Cannabis Use Clinical Trial
Official title:
Study of the Cannabis Use of Minors Imprisoned in the PACA Region (France)
NCT number | NCT03659942 |
Other study ID # | 2017-25 |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 2019 |
Est. completion date | June 2020 |
To date, there is little data on the consumption of young adults in detention.
The main objective of this project is to document the prevalence of problematic cannabis use
before incarceration among juveniles detained in the various detention centers in the PACA
Secondary objectives are to document:
- the prevalence of cannabis use over the course of life, last year and last month;
- the prevalence of harm and risky behavior associated with the use of a psychoactive
substance
- associated addictions and first and foremost tobacco
- the determinants (socio-demographic, socio-economic, environmental, etc.) of problem use
and cannabis use.
This is a multicenter cross-sectional study aimed at establishing an exhaustive picture of
the defined population region over a 12-month period.
The holder of the parental authority exercise and the individual agreeing to participate in
the study must:
- sign an informed consent a no objection card
- complete a car book and hetero-questionnaires. The time of handover is evaluated at 30
minutes.
The CAST questionnaire will be used to answer the main purpose of the study and to identify
consumers with problematic cannabis use.
CAST scores will be calculated. Abnormal CAST proportions will be presented along with their
95% confidence intervals. The links between the score and the various variables identified as
determinants will be tested using uni and multivariate analyzes.
The assessment of the health status and needs of this extremely vulnerable population is a
prerequisite for defining specific regional objectives and for establishing a coherent and
coordinated effective health intervention within the community. prisoner in France.
Status | Not yet recruiting |
Enrollment | 500 |
Est. completion date | June 2020 |
Est. primary completion date | January 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 18 Years |
Eligibility |
Inclusion Criteria: - Newcomer subject in detention, - Subject having been informed about the study and not expressing opposition to participating in the study. - Legal officer who was informed about the study and did not express any opposition to participate in the study. - Subject including French and able to fill self-questionnaires, and not presenting attacks of the severe cognitive functions Exclusion Criteria: Subject already incarcerated less than 6 months before its inclusion, - subject with severe hearing loss, - Subject not having agreed to participate in the study, - Holder of parental authority who has not given his consent, - Subject not including French. |
Country | Name | City | State |
---|---|---|---|
France | Assistance Publique Des Hopitaux de Marseille | Marseille | Paca |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique Hopitaux De Marseille |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | CAST questionnaire score | the CAST questionnaire will be used to answer the main objective of the study and to identify consumers with problematic cannabis use. This is a validated self-questionnaire in France (Legleye et al., 2011), specific to the adolescent population, which is interpreted according to the score obtained. It includes 6 items with answer modes coded from 0 to 4. The total score obtained by summing these 6 items can therefore vary from 0 to 24. We define users without risk for a score of less than 3, users with low risk for a score greater than or equal to 3 and less than 7, and finally those with a risk of problematic use for a score greater than or equal to 7 | 30 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03253926 -
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
|
Phase 1/Phase 2 | |
Completed |
NCT04060602 -
Personalized Feedback Intervention to Reduce Risky Cannabis Use.
|
N/A | |
Completed |
NCT01212081 -
Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
|
||
Recruiting |
NCT04988490 -
Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
|
||
Recruiting |
NCT05188404 -
Aging and Marijuana: Benefits, Effects, and Risks
|
||
Completed |
NCT03662737 -
VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
|
||
Not yet recruiting |
NCT05999383 -
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
|
Phase 2 | |
Terminated |
NCT04436055 -
Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
|
||
Active, not recruiting |
NCT04374773 -
Effects of Pregnancy-associated Hormones on THC Metabolism in Women
|
Phase 4 | |
Completed |
NCT04316741 -
Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use
|
N/A | |
Recruiting |
NCT05396638 -
Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder
|
N/A | |
Recruiting |
NCT05309226 -
Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health
|
||
Recruiting |
NCT03859089 -
Cannabis for Opioid Substitution Trial
|
||
Recruiting |
NCT05849636 -
Alerta Cannabis: Evaluation of Web-based Tailored Intervention
|
N/A | |
Enrolling by invitation |
NCT05521321 -
Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit
|
N/A | |
Recruiting |
NCT05119244 -
Environment and Lung Cancer
|
N/A | |
Recruiting |
NCT04841655 -
Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment
|
||
Terminated |
NCT04100590 -
Eye Tracking as a Biomarker of Cannabis Effects
|
Phase 2 | |
Completed |
NCT05167097 -
Mindsets and the Effectiveness of a Brief Intervention - Replication
|
N/A | |
Recruiting |
NCT04114903 -
Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity
|